EMA Approves Gilead Sciences’ Vemlidy for Use in Children Above 6 with Hepatitis B
April 29, 2023
Trending News ☀️
Gilead Sciences ($NASDAQ:GILD), Inc. is an American biopharmaceutical company that discovers, develops, and commercializes therapeutics to advance the care of patients suffering from life-threatening diseases. Recently, the European Medicines Agency (EMA) has granted approval for Gilead’s hepatitis B therapy, Vemlidy (tenofovir alafenamide), for use in children aged six and above. Vemlidy can reduce the levels of hepatitis B virus in the blood and reduce the risk of serious liver problems. Overall, the EMA’s approval of Vemlidy for use in children is a very positive step forward in improving pediatric care for hepatitis B. Gilead Sciences is leading the way in providing innovative treatments for a wide range of chronic conditions, and this new approval shows their commitment to providing therapeutic options to fight and treat life-threatening diseases.
Stock Price
On Friday, GILEAD SCIENCES‘ stock opened at $82.5 and closed at $82.2, down by 1.6% from its last closing price of 83.6. This decline followed news that the European Medicines Agency (EMA) had approved the company’s Vemlidy drug for use in children aged six and above suffering from chronic hepatitis B. Vemlidy, developed by Gilead Sciences, is a newly approved first-line therapy for the treatment of chronic hepatitis B in adults and children six years of age and older. The drug is intended to reduce the amount of hepatitis B virus in the body, helping to limit or stop the progression of liver damage.
The approval of Vemlidy will enable Gilead to expand its presence in the European market, bringing much needed relief to those suffering from hepatitis B. In recent years, the company has made significant investments in its research and development, leading to several promising new therapies. This latest approval of Vemlidy provides further evidence of the effectiveness and potential of Gilead’s drug pipeline. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Gilead Sciences. More…
| Total Revenues | Net Income | Net Margin |
| 27.28k | 4.59k | 27.3% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Gilead Sciences. More…
| Operations | Investing | Financing |
| 9.07k | -2.47k | -6.47k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Gilead Sciences. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 63.17k | 41.96k | 17.03 |
Key Ratios Snapshot
Some of the financial key ratios for Gilead Sciences are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 6.7% | 36.8% | 24.7% |
| FCF Margin | ROE | ROA |
| 30.6% | 19.9% | 6.7% |
Analysis
At GoodWhale, we analyze the wellbeing of GILEAD SCIENCES, and according to our Star Chart, GILEAD SCIENCES is strong in dividend, profitability, and medium in asset and weak in growth. This categorizes GILEAD SCIENCES as a ‘cow’, a type of company that has a track record of paying out consistent and sustainable dividends. With this information, investors who are interested in steady, long-term returns might be best suited for GILEAD SCIENCES. Furthermore, GILEAD SCIENCES has a high health score of 9/10 with regard to its cashflows and debt, indicating that the company is capable to pay off debt and fund future operations. More…
Peers
In the biopharmaceutical industry, competition is fierce. Among the companies vying for market share are Gilead Sciences Inc, Eli Lilly and Co, Amgen Inc, and SCYNEXIS Inc. All of these companies are working to develop new and innovative treatments for a variety of diseases.
– Eli Lilly and Co ($NYSE:LLY)
Eli Lilly and Co is a pharmaceutical company with a market cap of 316.8 billion as of May 2021. The company has a return on equity of 45.88% and is headquartered in Indianapolis, Indiana. Eli Lilly and Co develops and markets prescription medications and over-the-counter products. The company’s products are available in approximately 120 countries.
– Amgen Inc ($NASDAQ:AMGN)
Amgen Inc is a biopharmaceutical company with a market cap of 135.3B as of 2022. The company has a return on equity of 460.37%. Amgen Inc is a biopharmaceutical company that discovers, develops, manufactures, and delivers human therapeutics worldwide. The company offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and nephrology.
– SCYNEXIS Inc ($NASDAQ:SCYX)
SCYNEXIS Inc. is a biopharmaceutical company, which focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. The company’s lead product, SCY-078, is an oral and intravenous antifungal agent in Phase 3 clinical development for the treatment of serious and life-threatening invasive fungal infections. SCYNEXIS Inc. was founded by Peter R. Lupton, David P. Lupton and George W. Schmidt in December 1997 and is headquartered in Durham, NC.
Summary
This is a significant breakthrough in the fight against the disease and could open up a huge potential revenue stream for Gilead. Analysts are bullish on Gilead, as they believe that its pipeline of products and potential growth opportunities could lead to further share price appreciation in the future.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
